Related Experiment Video For CD117
Updated: Dec 9, 2025
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Expression of CD117, CD34, and VEGF proteins in progression from endometrial hyperplasia to endometrioid carcinoma
Wael Abdo Hassan1,2, Rehab Ibrahim1,3
1Department of Pathology, Faculty of Medicine, Suez Canal University Ismailia, Egypt.
Background:
The risk of endometrial hyperplasia progressing into endometrioid carcinoma ranges from 1% for benign hyperplasia to 46.2% for endometrial intra-epithelial neoplasia. Differentiation between both types of hyperplasia is thus crucial for optimal management. The present study investigates the expression of the following immune-histochemical markers, for their potential roles in differentiating between both types of endometrial hyperplasia; as well as their expression in endometrial carcinoma: VEGF, CD34 and CD117.
Methods:
Tissue samples were obtained, fixed, processed, stained by hematoxylin and eosin for diagnosis, and then imunohistochemically stained using anti CD117, CD34, and VEGF antibodies.
Results:
In benign endometrial hyperplasia, the cells show weak expression to VEGF and CD34, and absent CD117. In endometrial intra-epithelial neoplasia, the cells show strong expression of VEGF and weak expression of CD34 and CD117. In case of endometrioid carcinoma, all cases showed strong reaction for VEGF and CD34, and moderate expression to CD117.
Conclusion:
Our data suggests a role for CD117, CD34, and VEGF in progression from hyperplasia to carcinoma.
